Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Pharmacokinetics of Albiglutide in Normal and Renally Impaired Subjects.

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 7.0

Eligibility Criteria:
Inclusion Criteria:~* normal renal function or renal impairment~* stable hemodialysis treatment for at least 3 months before screening and able to tolerate a hemodialysis treatment lasting 3-4 hours with blood flow rates of \>200mL/min (cohort 3 only)~* neither pregnant nor lactating~* HbA1c 6-10.5% inclusive~* females of childbearing potential must be practicing adequate contraception.~Exclusion Criteria:~* inability to meet the PK objectives of the study~* history of hypoglycemia unawareness or severe hypoglycemia~* liver function tests greater than or equal to 2 times the ULN~* clinically significant cardiovascular and/or cerebrovascular disease~* positive test results for hepatitis B, hepatitis C, or HIV~* documented hypertension or hypotension at screening~* known hepatic or biliary abnormalities~* current use of sulfonylureas~* active history of tobacco use within 6 months before screening~* donation of blood in excess of 500mL within 56 days before albiglutide dosing~* receipt of any investigational drug within the 30days or 5 half lives, whichever is longer, before dosing~* previous or current receipt of exenatide or any other GLP-1 agonist

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Stage 1 normal renal function (Type: EXPERIMENTAL): Subject with estimated glomerular filtration rate (GFR) greater than 80 milliliter per minute (mL/min)
- Stage 1 moderate/severe renal function (Type: EXPERIMENTAL): Subject with estimated GFR \>= 20 mL/min and less than 50 mL/min
- Stage 2 normal renal function (Type: EXPERIMENTAL): Subject with GFR greater than 80 mL/min
- Stage 2 moderate renal impairment (Type: EXPERIMENTAL): Subject with estimated GFR \>= 30 mL/min and less than 50 mL/min
- Stage 2 subjects requiring hemodialysis (Type: EXPERIMENTAL): Subjects who require hemodialysis
- Stage 2 severe renal impairment not requiring hemodialysis (Type: EXPERIMENTAL): Subjects with GFR less than 30 mL/min
- Stage 2 mild renal impairment (Type: EXPERIMENTAL): Subjects with GFR \>= 50 mL/min and \<= 80 mL/min

Based on this trial design, predict the completion outcome and termination type (if applicable).